We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

AACC Releases Updated Guidance to Improve Use of POC Tests for Fertility and Reproductive Health

By LabMedica International staff writers
Posted on 05 Sep 2022
Print article
Image: AACC has issued new recommendations for performing POC tests for fertility and reproductive health (Photo courtesy of Pexels)
Image: AACC has issued new recommendations for performing POC tests for fertility and reproductive health (Photo courtesy of Pexels)

Point-of-care tests are clinical tests that are performed near the patient instead of in a central lab. Due to their convenience and rapid turnaround times, these tests can help patients to get treatment much faster than traditional tests. As a result, the use of point-of-care testing has risen steadily in all areas of healthcare. In the fertility and reproductive health fields in particular, it is now used for everything from predicting ovulation and diagnosing pregnancy to managing premature rupture of membranes (PROM) - also known as a patient's water breaking - and high-risk deliveries. However, when point-of-care tests are used inappropriately or performed incorrectly, this can lead to unnecessary follow-up tests and procedures and can even put the patient's health at risk or lead to death.

Now, the American Association for Clinical Chemistry (Washington, DC, USA) has issued a new guidance document with expert recommendations for performing point-of-care tests for fertility and reproductive health. As the use of point-of-care testing rises in these fields, this guidance is intended to ensure that patients and their babies fully benefit from it. AACC has updated guidance that it originally published in 2007 to inform healthcare professionals of the most current best practices for point-of-care testing in reproductive medicine. The highlights of the key recommendations from this document are:

  • Testing for PROM using commercial kits alone is not recommended without clinical signs that a patient's water has broken. Additionally, results from these tests must be interpreted in the context of a patient's clinical presentation to prevent patient harm.
  • Urine luteinizing hormone tests are accurate and reliable predictors of ovulation. These tests can improve the likelihood of conception among healthy fertile women and can also be used to time certain assisted reproduction procedures. However, further study is still needed to determine the efficacy of at-home ovulation prediction kits that use saliva or measure basal body temperature.
  • While blood laboratory pregnancy tests are the gold standard, healthcare providers should consider using pregnancy point-of-care tests in situations where rapid diagnosis of pregnancy is needed for treatment decisions. One such scenario is if a patient presents to the emergency department with unstable vital signs and symptoms indicative of a ruptured ectopic pregnancy that might require surgery.

"Point-of-care testing is growing in popularity as a means of delivering faster turnaround time of test results closer to the patient," said the guidance document authors Drs. James H. Nichols, Mahesheema Ali, John I. Anetor, Li-Sheng Chen, Yu Chen, Sean Collins, Saswati Das, Sridevi Devaraj, Lei Fu, Brad S. Karon, Heba Kary, Robert D. Nerenz, Alex J. Rai, Zahra Shajani-Yi, Vinita Thakur, Sihe Wang, Hoi-Ying Elsie Yu, and Lindsey E. Zamora. "Guidance is needed for optimizing the implementation of [point-of-care testing] in patient care. This guidance document revises previous recommendations and offers best practices for the use of [point-of-care testing] in fertility and reproductive health."

Related Links:
AACC 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A massive study has identified new biomarkers for renal cancer subtypes, improving diagnosis and treatment (Photo courtesy of Jessica Johnson)

Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes

Renal cell carcinomas (RCCs) are notably diverse, encompassing over 20 distinct subtypes and generally categorized into clear cell and non-clear cell types; around 20% of all RCCs fall into the non-clear... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more